Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma
Histamine dihydrochloride is a vasoactive biogenic amine. It inhibits the reactive oxygen species formation in monocytes via histamine H2 receptors and protects natural killer and T cells from oxidative damage. Histamine has the potential to optimize cytokine-induced activation of T cells and natura...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 Apr 2008
|
| In: |
Future oncology
Year: 2008, Volume: 4, Issue: 2, Pages: 169-177 |
| ISSN: | 1744-8301 |
| DOI: | 10.2217/14796694.4.2.169 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/14796694.4.2.169 Verlag, lizenzpflichtig, Volltext: https://www.futuremedicine.com/doi/10.2217/14796694.4.2.169 
|
| Author Notes: | Jolanta B. Perz, Anthony D. Ho |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 177339438X | ||
| 003 | DE-627 | ||
| 005 | 20240414193446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211012s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/14796694.4.2.169 |2 doi | |
| 035 | |a (DE-627)177339438X | ||
| 035 | |a (DE-599)KXP177339438X | ||
| 035 | |a (OCoLC)1341421733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dengler, Jolanta |d 1972- |e VerfasserIn |0 (DE-588)121586138 |0 (DE-627)705556344 |0 (DE-576)292785291 |4 aut | |
| 245 | 1 | 0 | |a Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma |c Jolanta B. Perz, Anthony D. Ho |
| 264 | 1 | |c 11 Apr 2008 | |
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.10.2021 | ||
| 520 | |a Histamine dihydrochloride is a vasoactive biogenic amine. It inhibits the reactive oxygen species formation in monocytes via histamine H2 receptors and protects natural killer and T cells from oxidative damage. Histamine has the potential to optimize cytokine-induced activation of T cells and natural killer cells; therefore, the addition of histamine to cytokine treatment may improve treatment efficacy. Clinical trials in solid tumors and in acute myeloid leukemia have demonstrated the potential to improve treatment outcome when histamine dihydrochloride is combined with immunotherapy. In patients with metastatic malignant melanoma, this strategy improved remission rates and increased survival. On the other hand, less promising results were reported for histamine dihydrochloride added to cytokines in patients with other solid tumors, especially in advanced renal cell carcinoma. A recent international Phase III trial performed in 320 patients showed that maintenance therapy with histamine dihydrochloride and IL-2 was able to improve leukemia-free survival in patients with acute myeloid leukemia, without an effect on overall survival. The combination of histamine dihydrochloride with IL-2 potentially offers an efficacious and tolerable maintenance strategy for patients with acute myeloid leukemia; however, its impact on survival remains to be explored. | ||
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a AML | |
| 650 | 4 | |a histamine | |
| 650 | 4 | |a IFN-α | |
| 650 | 4 | |a IL-2 | |
| 650 | 4 | |a malignant melanoma | |
| 650 | 4 | |a renal cell carcinoma | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology |d London : Taylor & Francis, 2005 |g 4(2008), 2, Seite 169-177 |h Online-Ressource |w (DE-627)484405055 |w (DE-600)2184533-5 |w (DE-576)398100217 |x 1744-8301 |7 nnas |a Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma |
| 773 | 1 | 8 | |g volume:4 |g year:2008 |g number:2 |g pages:169-177 |g extent:19 |a Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.2217/14796694.4.2.169 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.futuremedicine.com/doi/10.2217/14796694.4.2.169 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211012 | ||
| 993 | |a Article | ||
| 994 | |a 2008 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 121586138 |a Dengler, Jolanta |m 121586138:Dengler, Jolanta |d 910000 |d 910100 |e 910000PD121586138 |e 910100PD121586138 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN177339438X |e 3988762377 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"11 Apr 2008","dateIssuedKey":"2008"}],"name":{"displayForm":["Jolanta B. Perz, Anthony D. Ho"]},"recId":"177339438X","person":[{"given":"Jolanta","display":"Dengler, Jolanta","family":"Dengler","role":"aut"},{"display":"Ho, Anthony Dick","given":"Anthony Dick","family":"Ho","role":"aut"}],"title":[{"title_sort":"Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma","title":"Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma"}],"language":["eng"],"id":{"doi":["10.2217/14796694.4.2.169"],"eki":["177339438X"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"19 S."}],"note":["Gesehen am 12.10.2021"],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2005 -"],"disp":"Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinomaFuture oncology","recId":"484405055","language":["eng"],"part":{"issue":"2","extent":"19","volume":"4","text":"4(2008), 2, Seite 169-177","pages":"169-177","year":"2008"},"id":{"zdb":["2184533-5"],"issn":["1744-8301"],"eki":["484405055"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 28.05.2024"],"origin":[{"publisherPlace":"London ; London","dateIssuedKey":"2005","dateIssuedDisp":"2005-","publisher":"Taylor & Francis ; Future Medicine Ltd"}],"title":[{"title":"Future oncology","title_sort":"Future oncology"}]}]} | ||
| SRT | |a DENGLERJOLHISTAMINED1120 | ||